NEW YORK (GenomeWeb News) – An investigator at the Cedars-Sinai Oschin Comprehensive Cancer Institute has landed a $300,000 in funding from the Avon Foundation for Women to study blood-based biomarkers that could be used to treat and stratify breast cancer patients.

Associate Professor Dolores Di Vizio plans to use the funding to study miRNAs found in oncosomes, large bioactive lipid-enclosed vesicles that originate in tumor cells and circulate in plasma, with a focus on how they might be used to indicate tumor progression.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.